Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Montreal, Quebec H3T 1E2, Canada.
BMJ. 2013 Jan 8;346:e8525. doi: 10.1136/bmj.e8525.
To assess whether a double therapy combination consisting of diuretics, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers with addition of non-steroidal anti-inflammatory drugs (NSAIDs) and the triple therapy combination of two of the aforementioned antihypertensive drugs to which NSAIDs are added are associated with an increased risk of acute kidney injury.
Retrospective cohort study using nested case-control analysis.
General practices contributing data to the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics database.
A cohort of 487,372 users of antihypertensive drugs.
Rate ratios with 95% confidence intervals of acute kidney injury associated with current use of double and triple therapy combinations of antihypertensive drugs with NSAIDs.
During a mean follow-up of 5.9 (SD 3.4) years, 2215 cases of acute kidney injury were identified (incidence rate 7/10,000 person years). Overall, current use of a double therapy combination containing either diuretics or angiotensin converting enzyme inhibitors or angiotensin receptor blockers with NSAIDs was not associated with an increased rate of acute kidney injury. In contrast, current use of a triple therapy combination was associated with an increased rate of acute kidney injury (rate ratio 1.31, 95% confidence interval 1.12 to 1.53). In secondary analyses, the highest risk was observed in the first 30 days of use (rate ratio 1.82, 1.35 to 2.46).
A triple therapy combination consisting of diuretics with angiotensin converting enzyme inhibitors or angiotensin receptor blockers and NSAIDs was associated with an increased risk of acute kidney injury. The risk was greatest at the start of treatment. Although antihypertensive drugs have cardiovascular benefits, vigilance may be warranted when they are used concurrently with NSAIDs.
评估由利尿剂、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂与非甾体抗炎药(NSAIDs)联合组成的双药治疗组合,以及加入 NSAIDs 的上述两种降压药中的两种组成的三药治疗组合是否与急性肾损伤风险增加相关。
使用嵌套病例对照分析的回顾性队列研究。
向英国临床实践研究数据链提供数据的普通诊所,该数据链与医院发病统计数据库相关联。
使用抗高血压药物的 487372 名患者队列。
与当前使用含有 NSAIDs 的双药和三药抗高血压药物组合相关的急性肾损伤的发生率比及其 95%置信区间。
在平均 5.9(SD 3.4)年的随访期间,确定了 2215 例急性肾损伤病例(发生率为 7/10000 人年)。总体而言,当前使用含有利尿剂或血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂与 NSAIDs 的双药治疗组合与急性肾损伤发生率增加无关。相比之下,当前使用三药治疗组合与急性肾损伤发生率增加相关(发生率比 1.31,95%置信区间 1.12 至 1.53)。在二次分析中,在使用的前 30 天观察到了最高的风险(发生率比 1.82,1.35 至 2.46)。
由利尿剂与血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂和 NSAIDs 组成的三药治疗组合与急性肾损伤风险增加相关。在开始治疗时风险最大。尽管抗高血压药物具有心血管益处,但当它们与 NSAIDs 同时使用时,可能需要保持警惕。